Mode
Text Size
Log in / Sign up
N/A N=310 Randomized Treatment

Pragmatic Urinary Sodium-based Treatment algoritHm in Acute Heart Failure

Heart Failure Acute

Enrolled (actual)
310
Serious AEs
41.9%
Results posted
Apr 2024
Primary outcome: Primary: Total Natriuresis After 24 Hours — 409; 345 mmol

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Natriuresis (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University Medical Center Groningen
Primary completion
May 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Total Natriuresis After 24 Hours
409; 345
PRIMARY
First Occurrence of All-cause Mortality or Heart Failure Rehospitalization After 180 Days
46; 50
SECONDARY
48-hours Natriuresis
SECONDARY
72-hours Natriuresis
SECONDARY
Length of Hospital Stay
SECONDARY
Percentage Change in NT-proBNP at 48 Hours
SECONDARY
Percentage Change in NT-proBNP at 72 Hours

Summary

Administration of loop diuretics to achieve decongestion is the current cornerstone of therapy for acute heart failure. Unfortunately, there is a lack of evidence of how to guide diuretic treatment. Recently, urinary sodium, as a response measure of diuretic response, has been proposed as a target for therapy. The hypothesis of this study is that natriuresis guided therapy in patients with acute heart failure will improve diuretic response, decongestion, and reduce length of hospital stay, as well as heart failure rehospitalisations.

Eligibility Criteria

Inclusion Criteria

  • Male or female ≥ 18 years of age
  • Primary diagnosis of acute /decompensated heart failure as assessed by treating physician

a. Acute Heart failure can be de novo or exacerbation of known heart failure and diagnosis is based on criteria in the ESC HF guidelines

  • Requirement of intravenous diuretic use

Exclusion Criteria

  • Dyspnoea primarily due to non-cardiac causes
  • Patients with severe renal impairment receiving dialysis or requiring ultrafiltration
  • Inability to follow instructions
  • Any other medical conditions that may put the patient at risk or influence study results in the investigator's opinion, or that the investigator deems unsuitable for the study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04606927). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search